MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.
about
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.Limitations and opportunities of non-invasive liver stiffness measurement in children.Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans.Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).Non-alcoholic fatty liver disease-a chronic disease of the 21(st) century.Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.Diagnosis of Nonalcoholic Steatohepatitis Without Liver Biopsy.The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans.Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor NAFLD - authors' reply.Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions.Non-invasive Evaluation of NAFLD with Indocyanine Green Clearance Test: a Preliminary Study in Morbidly Obese Patients Undergoing Bariatric Surgery.Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders.Repeatability and Reproducibility of the Ultrasonic Attenuation Coefficient and Backscatter Coefficient Measured in the Right Lobe of the Liver in Adults With Known or Suspected Nonalcoholic Fatty Liver Disease.Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes.Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials.Liver volume and hepatic adiposity in childhood: relations to body growth and visceral fat.Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research.Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease.Prevalent Cardiovascular Disease Events and T1 Mapping Defined Hepatic Fibrosis.NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease.Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.Obesity and nonalcoholic fatty liver disease: current perspectivesAssociation between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years oldTherapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related MechanismsCurrent status of imaging in nonalcoholic fatty liver diseaseEvaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN)Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
P2860
Q30238749-FC562CC0-8F76-4482-9EEB-7886A0CB9C5CQ30360182-0BD0E4BA-BC0D-4D89-B94A-5080D9BDDA25Q33794679-721AE544-8071-417B-AD67-CB473F8C657BQ38806840-802EF3F9-3353-4BAC-A166-B22C036C0F02Q39062084-1E9C40D0-099D-47C7-8891-C6BBD68E78DCQ39170830-651FD303-3016-4811-89E7-71DE8875DFA5Q39333577-4AD79D26-4E67-42A6-9473-87F05C8A9A4CQ40154653-FD7747BC-1D5F-43D2-A43A-B4971EA51D73Q40354046-2156F17B-791E-41BF-A1E1-6C67BE62B932Q40367115-A207E5DE-3B7C-4597-8D12-653691F3EB73Q40444861-2C3B07F1-4904-4CF0-B765-3FC6F4D4DC35Q40581820-03C545B1-DDBD-4A4F-8A4A-4441AC89488FQ40976920-0DB2508A-694E-4049-9F4C-C1E9C7181B30Q45067109-9E1CCC3F-1025-4EF9-AD0B-58CE7BE7E86BQ45942296-6F876FAD-09F3-4BB3-8541-84D455662CFEQ45988896-F2F3C934-771A-4C7E-8CA5-40902E15362CQ46220517-2C4FBE19-916F-4B62-9359-A3B265E848D5Q46323715-875AC297-DF04-4A5D-9E15-9A63883CECAEQ46476704-A776A0E7-7AE9-4E3E-8E36-DE21AE96AA35Q47256094-335B53D9-2148-484C-A3C1-75B309FCD3C2Q47546971-9454FF21-71DF-47C4-A62B-C96107F27E7FQ48187865-7796B506-602E-4E3F-92B9-6BE27748D2BEQ48206358-FFC0BFA3-8E15-4F26-B636-04A6031CB0CBQ49884186-8756F269-F528-456D-ACB3-27789EA57FEBQ50026039-83F39AEE-A4D6-4A42-A2DA-F8054FDACE5EQ52661700-1FD22B44-8684-4B2C-9D17-B028916CD9CCQ52699058-C9547402-6279-42AE-A59D-D6E51AA503CFQ53703261-7E14E22C-7997-4CB4-BE6E-3BDCC78293BFQ54232638-1C77FDA6-683E-4954-9D83-9678DD27AB96Q55401392-B2E36604-9D94-4DB3-AC83-C02A8E3F4A2EQ55715558-5437156C-8620-4DBE-84D8-9F6AB88A66FDQ57069715-146898BB-C7A2-4ED1-8A40-ED4B001043AEQ57930167-790A8944-5E46-44F9-8C9C-4EE2D041CE46Q58122029-1639CB14-868A-414F-88F1-5D6447D5AB7EQ58700636-B663A370-E24E-4BE5-AE21-F71C310461C6Q58734575-6F96BD64-7859-4425-B9BB-E8D737072F49Q58760217-3508A7C1-580F-4D3D-B2CF-54ABE1293113
P2860
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
MRI and MRE for non-invasive q ...... l trials to clinical practice.
@en
type
label
MRI and MRE for non-invasive q ...... l trials to clinical practice.
@en
prefLabel
MRI and MRE for non-invasive q ...... l trials to clinical practice.
@en
P2093
P2860
P1476
MRI and MRE for non-invasive q ...... l trials to clinical practice.
@en
P2093
Claude B Sirlin
Parambir S Dulai
Rohit Loomba
P2860
P304
P356
10.1016/J.JHEP.2016.06.005
P577
2016-06-13T00:00:00Z